Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $10.40.

IRWD has been the subject of several recent research reports. Craig Hallum cut their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating for the company in a report on Friday, August 9th. Wells Fargo & Company cut their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating on the stock in a report on Friday, August 9th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a "hold" rating in a report on Monday, September 9th. Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a "market perform" rating and a $5.00 target price on the stock. Finally, Capital One Financial lowered Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $12.00 to $4.00 in a report on Thursday, August 8th.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its holdings in Ironwood Pharmaceuticals by 244.8% during the first quarter. Russell Investments Group Ltd. now owns 777,847 shares of the biotechnology company's stock valued at $6,775,000 after purchasing an additional 552,227 shares in the last quarter. Entropy Technologies LP bought a new position in Ironwood Pharmaceuticals during the 1st quarter worth approximately $693,000. First Eagle Investment Management LLC increased its position in shares of Ironwood Pharmaceuticals by 10.5% in the 1st quarter. First Eagle Investment Management LLC now owns 1,002,225 shares of the biotechnology company's stock valued at $8,729,000 after buying an additional 95,000 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Ironwood Pharmaceuticals by 339.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 195,057 shares of the biotechnology company's stock worth $1,699,000 after purchasing an additional 150,663 shares during the period. Finally, Edgestream Partners L.P. bought a new position in Ironwood Pharmaceuticals in the first quarter valued at approximately $2,581,000.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock traded down $0.48 during mid-day trading on Tuesday, hitting $4.30. 779,889 shares of the stock traded hands, compared to its average volume of 2,931,142. Ironwood Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $15.70. The firm has a market cap of $686.88 million, a price-to-earnings ratio of -147.67 and a beta of 0.47. The company's 50-day simple moving average is $4.32 and its 200-day simple moving average is $5.55.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business's revenue was down 19.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.12 earnings per share. Analysts forecast that Ironwood Pharmaceuticals will post 0.26 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.